Zydus Life Gains 3% on Positive Brokerage Report
Zydus Life shares rise nearly 3% after a favorable brokerage report. Source: ScoutQuest
Stock news timeline · ZYDUSLIFE
Zydus
News timeline · Last 30 days
23 Aug 2026 – 21 Sep 2026 · Times in IST
- Timeline updates
- 21
- Bullish
- 9
- Neutral
- 12
- Bearish
- 0
- Active days
- 10
News timeline
Showing 21 of 21 updates · Newest first
No matching updates
Change the keyword or sentiment above, then click Apply.
Friday, 18 Sep 20263 updates
Zydus Life: Bernstein on Zydus Life Maintains Outperform with Target Price of ₹1,457 as Novartis discontinuing VHB937 improves the commercial landscape for Usnoflast in ALS, with positive success prospects, US FDA priority review and orphan designation supporting potential high returns if Phase IIb data demonstrates meaningful efficacy.
Bernstein Rates Zydus Life 'Outperform'; ₹1,457 Target Set
Bernstein rates Zydus Life as outperform with a target price of ₹1,457. Novartis halts VHB937 for ALS, boosting Zydus' Usnoflast prospects with $100M potential. Source: ScoutQuest
Friday, 11 Sep 20262 updates
CRISIL Reaffirms Zydus AAA Rating
CRISIL reaffirms Zydus Lifesciences' credit ratings; long-term CRISIL AAA/Stable. Short-term rating retained at CRISIL A1+ with no changes announced. Source: ScoutQuest
Zydus to Join J.P. Morgan India Conf on Sep 21
Zydus Lifesciences Ltd to participate in J.P. Morgan India Conference 2026 on Sep 21. Company Secretary notified exchanges to inform investors about the event. Source: BSE
Monday, 07 Sep 20261 update
Zydus Lifesciences Sees ₹20 Cr Block Trade at ₹1,138.80/Share
Zydus Lifesciences executed NSE block trade of 176,222 shares worth ₹20.07 crore. Trade price settled at ₹1,138.80 per share during the transaction. Source: Livesquawk
Saturday, 05 Sep 20261 update
Zydus Subsidiary Settles US Drug Pricing Case for $5.9M
Zydus Lifesciences' subsidiary settled US generic drug pricing litigation for $5.9M. The settlement resolves claims by Indirect Reseller Plaintiffs without admission of fault. Source: ScoutQuest
Tuesday, 01 Sep 20261 update
Zydus Plans ₹1,100 Cr Buyback, Reports 17% Revenue Growth
Zydus Lifesciences conducted its 31st AGM virtually on Aug 11, 2026, chaired by Pankaj Patel, with key business updates and resolutions discussed. Key highlights included 17% revenue growth in FY26, a Rs. 1,100 crore buyback plan, strong R&D investment, and sustainable energy achievements. Source: BSE
Monday, 31 Aug 20265 updates
Zydus Drug Clears Key Goal in Global MASH Trial
Zydus Lifesciences' Saroglitazar achieved primary goal in global Phase II(b) MASH trial. The EVIDENCES X study with 189 subjects showed steatohepatitis resolution without worsening fibrosis after 52 weeks. Source: The Economic Times
Zydus Rises on Positive MASH Drug Trial Results
Zydus Lifesciences announces positive Phase II(b) trial results for Saroglitazar Mg in MASH, achieving primary endpoint with no fibrosis worsening. The trial showed improvements in liver parameters; data will be presented at scientific meetings and submitted for journal publication. Source: BSE
Zydus Drug Passes Phase II for MASH
Zydus Lifesciences' Saroglitazar showed positive Phase II trial results for MASH treatment. The trial met its primary goal and involved 189 patients over 52 weeks globally. Source: ScoutQuest
Zydus Gains on Positive Saroglitazar Trial Results in MASH
Zydus Lifesciences reports positive Phase II(B) Evidence-X trial results for saroglitazar MG in MASH. The trial achieved its main goal of resolving steatohepatitis without increasing fibrosis. Source: Livesquawk
Zydus Lifesciences: Reports Good Results From Its Evidence-X Phase II(B) Clinical Trial For Saroglitazar MG In MASH; The Trial Met Its Main Goal Of Resolving Steatohepatitis Without Increasing Fibrosis.
Thursday, 27 Aug 20263 updates
Zydus Sees ₹24.58 Cr NSE Block Deal at ₹1,173.20
Zydus Lifesciences saw an NSE block trade worth ₹24.58 cr for ~209,489 shares at ₹1,173.20. Source: Livesquawk
Zydus Life: Macquarie on Zydus Life Maintains Outperform with Target Price of ₹1,285 as strategic mix shift is expected to lift EBITDA margins to 27–28%, Saroglitazar and a robust US generics pipeline strengthen growth visibility, while domestic business is expected to outgrow IPM by 300–500bps and international formulations and consumer wellness remain growth drivers.
Macquarie Targets ₹1,285 for Zydus on MedTech, US Growth Plans
Macquarie maintains 'Outperform' on Zydus Lifesciences, targets Rs 1,285, citing focus on branded businesses, innovative therapies, and MedTech. Zydus plans 30+ US launches annually, expects Saroglitazar peak sales of $250-400M, and aims for EBITDA margins of 27-28% by FY27. Source: NDTV Profit
Wednesday, 26 Aug 20263 updates
Zydus Sets Up ₹5 Cr Treasury Arm, Operations Pending
Zydus Lifesciences establishes subsidiary Zydus Global Treasury Centre IFSC Ltd. Subsidiary's authorized and paid-up capital is Rs. 5 Cr; operations yet to commence. Source: ScoutQuest
Zydus Sets Up Treasury Hub in Gift City for Global Expansion
Zydus Lifesciences forms Zydus Global Treasury Centre IFSC Ltd in Gift City. The subsidiary is based in Gandhinagar, indicating expansion efforts by Zydus. Source: Livesquawk
Zydus Lifesciences: Co. Incorporates Unit Named Zydus Global Treasury Centre Ifsc Limited In Gift City, Gandhinagar.
Monday, 24 Aug 20261 update
Zydus Moves 32,577 Shares Within Promoter Group
Zydus Lifesciences transferred 32,577 shares within promoter group. Shares moved from Late Jasodaben Patel to Prashant Patel under SEBI norms. Source: ScoutQuest
Sunday, 23 Aug 20261 update
Zydus Targets $3.02Bn Revenue by FY26 with Focus on Innovation
Zydus Lifesciences presented its corporate overview, showcasing FY26 revenue of $3.02bn and R&D spend of $257mn, with a focus on innovation-led growth. Key highlights include biosimilars, vaccines, MedTech advancements, and strategic moves in US and international markets for specialty and generic products. Source: BSE